Purpose of review The present review highlights sentinel work published since 2006 on the definition of the transplantation barrier and the elucidation of cytokine and immune response gene variation in defining posttransplant risks.
Introduction
Major advances in the field of immunogenetics have contributed to the success of allogeneic hematopoietic cell transplantation (HCT) as a curative modality. The availability of DNA-based methods for typing the highly polymorphic human leukocyte antigen (HLA) genes has provided new information regarding the functional consequences of allelic variation. Currently, the standard for the selection of unrelated donors (URDs) includes highresolution typing and matching for HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 alleles. Although allele identity between the transplant recipient and URD can lower the risks of clinically significant acute graft-versus-host disease (GVHD), chronic GVHD, and mortality, matching for HLA genes does not guarantee that these complications will not occur. Clinical GVHD can be observed in as many as 60% of well matched transplant recipients depending on the immunosuppressive regimen. Recent evidence strongly suggests that genetic variation within the major histocompatibility complex (MHC) residing outside of the coding regions of the classical HLA genes can contribute to increased posttransplant risks even after HLA-matched transplantation. Furthermore, polymorphism in cytokine genes and immune response genes plays an important role in modulating the effects of tissue injury that constitute the GVHD syndrome.
The major histocompatibility complex
In this section, we will present new data on locus-specific risks and the significance of extended MHC haplotypes.
Matching for classical human leukocyte antigen genes
Donor-recipient matching for the classical HLA genetic loci, HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 has served as the cornerstone of unrelated HCT. Although the importance of the HLA system in transplantation has been well defined for several decades, investigation into the functional significance of sequence polymorphism of class I and II genes has been feasible since the late 1980s when PCR technology became available. Since then, the clinical significance of donor matching has been defined [1 ,2-9].
Recently, an analysis of a large cohort of URD transplants facilitated by the National Marrow Donor Program (NMDP) has shed new light on the relative importance of matching for HLA genes [1 ] . A total of 3860 patients and their URDs were evaluated for locus-specific risks. When compared with patients matched at all five HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 loci ('10/10' matched), the presence of a single mismatch was associated with adverse outcome, with the exception of single HLA-DQB1 locus mismatches. These results indicate that a single HLA-DQ mismatch is better tolerated than HLA-A, HLA-B, HLA-C or HLA-DRB1 mismatches; when no matched donor can be identified, then use of a donor with a single HLA-DQ mismatch might be acceptable. Transplantation from HLA-A, HLA-B, HLA-C, HLA-DRB1-matched donors ('8/8' matched) yields outcomes equivalent to that after 10/10 matching. Mismatching for two or more determinants, however, was associated with increased risk of acute GVHD and mortality. HLA-DQB1 disparity was detrimental when mismatching at other HLA loci was also present; therefore, when a donor is already known to have one HLA-A, HLA-B, HLA-C, or HLA-DRB1 mismatch, prospective HLA-DQB1 typing may help to define the total number of mismatches.
Permissible human leukocyte antigen mismatches
The concept that alloreactivity could be mapped to discrete residues of the HLA molecule, which participate in defining peptide binding or direct contact with the T-cell receptor, was initially shown by Ferrara et al. [10] . In this study, risks associated with donor-recipient amino acid mismatching at key residues of the HLA-B molecule were measured. Disparity at residue 116 was associated with increased risk of clinically significant acute GVHD and transplant-related mortality (TRM) compared with matching at this residue.
Extension of the Ferrara observations were recently made by the Japan Marrow Donor Program (JMDP) in 4866 URD-recipient pairs [11 ] . Donor-recipient disparity for Tyr9-Phe9 of HLA-A and Tyr9-Ser9, Asn77-Ser77, Lys80-Asn80, Tyr99-Phe99, Leu116-Ser116, and Arg156-Leu156 of HLA-C were each associated with significantly increased risks of severe acute GVHD. A similar theme is emerging for epitopes encoded by HLA-DP [9, 12] . These studies demonstrate the importance of correlating structure with function as a clinically relevant tool for donor selection.
Human leukocyte antigen haplotypes
High-resolution typing methods for URD matching provides a surrogate for the haplotype matching that is feasible between genotypically identical siblings. Even though URDs and recipients may share the same HLA alleles, the alleles may be encoded on different haplotypes. The concept that the haplotype may define a series of markers, some detected, others undetected, which can be used to map functionally significant variation, has been applied in many models. Substantial information is currently available on the extensive sequence variation encoded within the MHC and its organization on haplotypes [13 ] . The complete sequencing of several common European haplotypes demonstrates that the full extent of MHC region variation has not yet reached a plateau. These data strongly suggest that haplotype-based approaches are needed for fine mapping of functional variation. As the MHC harbors regions of high linkage disequilibrium, haplotype-based approaches can serve as powerful tools for identifying variation that cause disease [14] [15] [16] [17] .
To test the hypothesis that novel undetected MHC resident variation encoded on HLA haplotypes could be responsible for posttransplant risks after HLA allele matched URD transplantation, a novel method for phasing HLA alleles has recently been developed to define the physical linkage of HLA-A, HLA-B and HLA-DRB1 alleles [18] . Given that HLA-B maps 1.4 Mb centromeric to HLA-A and 1.2 Mb telomeric to HLA-DRB1, HLA-B was used as a point of separation for the two haplotypes using arrays of HLA-B-specific oligonucleotide probes. Application of the phasing method to 10/10 allelematched URD-recipient pairs uncovered a 20% frequency of haplotype mismatching which was associated with significantly increased risk of clinically severe acute GVHD [19 ] .
These results suggest that untyped variation carried on the HLA haplotype might cause GVHD after HLA matched unrelated HCT, either from donor-recipient mismatching and from the direct effects of the variation or both. Evidence to support a role for haplotypeassociated variation has recently been established in two studies [20, 21] that have employed microsatellite markers as a mapping tool. In a study of Japanese patients [20] , polymorphism of the tumor necrosis factor (TNF) complex residing in the class III region of the MHC correlated with lower survival among patients who developed GVHD. The identification of functional MHC variation in the regions of class I, II and III has been observed in a large retrospective analysis of 10/10 matched donor-recipient pairs of Caucasian background [21] .
Practical applications
Haplotypes have been used to define optimal URD registry size and composition, and to predict the likelihood that a potential URD typed at low resolution for HLA-A, HLA-B, HLA-DR loci will be allele matched at HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1. The use of haplotype probabilities may increase the efficiency of an URD search and aid in prioritizing confirmatory typing of donors who are most likely allele matched with the recipient. To meet these needs, statistical methods have been developed to infer haplotypes when family data are not available, as in the case of URDs. Application of haplotype-inference methods to URD registry data must be robust enough to accommodate incomplete HLA genotype information, or variable levels of resolution of HLA alleles [22,23 ,24,25] . Owing to the strong positive, long-range linkage disequilibrium within the MHC, knowledge of the three-locus HLA-A, HLA-B, HLA-DR haplotype is descriptive of higherresolution definition of the extended haplotype [23 ] .
Use of haplotypes for recruitment of unrelated donors
To meet the needs of patients initiating a search for an URD, registries must have donors with both common and unique phenotypes. Several approaches for donor recruitment have been taken, including minority recruitment to increase the HLA diversity and to increase the probability that patients with uncommon phenotypes will identify suitable donors [26] . A novel approach for donor recruitment has recently been described in a study by the DKMS German Bone Marrow Donor Center [27 ] . This study demonstrates that it is feasible to increase the diversity of a donor registry by recruiting the relatives of registered donors who have rare HLA phenotypes. In this way, the proportion of donors with uncommon phenotypes can be successfully recruited.
Non-major histocompatibility complex genetic factors affecting transplant outcome
In this section, we will summarize new information on the clinical significance of cytokine and immune response gene variation and GVHD.
Genetic variants encoding non-major histocompatibility complex transplant determinants (minor histocompatibility antigens)
Non-MHC polymorphisms occurring throughout the genome encode transplant determinants known as minor histocompatibility antigens (mHAs) [28] . GVHD in HLA-identical sibling donor [matched-related donor (MRD)] HCT is attributable to mHA antigens. As MRD pairs share 50% of their genomes and minimal sharing occurs between URD pairs, disparity for mHA and the risk of GVHD must be greater in the latter [29] . Although accounting quantitatively for mHA disparity could greatly facilitate donor selection, currently there is no technology available capable of measuring the total mHA burden for any given transplant pair.
Genetic variants affecting the function of immune response genes
In addition to genetic diversity that causes disparity for mHA, there is in every individual extensive polymorphism that determines gene function and controls phenotype. This variation includes single nucleotide polymorphisms (SNPs) and structural differences known as copy number variation (CNV) polymorphisms. The majority of genetic variation has no functional significance; however, selected SNPs and CNV and short tandem repeats (microsatellite) can serve as useful markers for functional variants because of the significant linkage disequilibrium that occurs across distances as long as several hundred kilobases.
Genetic variation affects function by regulating transcription and alternative exon splicing, and encoding critical amino acid substitutions. Through various mechanisms, these functional polymorphisms control immune response genes (IRGs) by regulating the activity immune cells, receptors and cytokines, and by modulating the strength of the inflammatory response. Functional variation can also affect immunity involved in resistance to bacterial, fungal and viral disease, as well as other pathways impacting HCT outcome such as drug metabolism and the toxicity of cytotoxic therapy.
Immune response gene polymorphisms associated with acute GVHD and transplant-related mortality: the proinflammatory cytokine tumor necrosis factor
The first report suggesting that non-MHC polymorphisms might affect HCT outcome utilized microsatellite markers linked to candidate IRGs known to play important roles in modulating the alloimmune response. Middleton et al. [30] reported results of an analysis of TNFd, a dinucleotide (G/A genotype) microsatellite located within the TNF gene complex, in 49 MRD HCT and found an association with acute GVHD. In a follow-up study [31] , the same group further demonstrated an association of the TNFd3 allele with TRM. However, subsequent studies of TNF promoter region SNPs by Socie et al. [32] and Lin et al. [33] in cohorts of 100 and 570 MRD cases, respectively, found no association with acute GVHD or TRM, whereas Bogunia-Kubink et al. [34] reported an association of TNFA and TNFB genotypes with toxicity but not GVHD. A study of a SNP mapping to an intron in the TNF gene in 160 MRD transplants by Mullighan et al. [35] reported associations with acute and chronic GVHD but not TRM. Keen et al. [36] studied TNF in 182 URD cases and found an association with TRM but not GVHD.
Studies of the regulatory cytokine interleukin-10
The first published study of IL-10 variation in HCT, by Middleton et al. [30] reported the association of a microsatellite polymorphism, IL-10G, located at position À1064 in the promoter region of the IL-10 gene of the patient with acute GVHD in MRD cases. This association was reinforced in a follow-up study by the same group in 144 HCT cases [37] . Takahashi et al. [38] analyzed the IL-10G microsatellite in 62 HCT cases and found an association of high repeat numbers (>13 alleles) in the donor with chronic but not acute GVHD. Rocha et al. [39] studied 107 MRD cases and found an association of the IL-10G microsatellite in the patient with chronic GVHD, but not with acute GVHD or TRM. Overall, associations of IL-10 promoter region variation with GVHD or TRM have been demonstrated in at least 10 different studies [32, 33, [35] [36] [37] [38] [39] [40] [41] [42] . Lin et al. [33] reported a two-phase discovery and validation analysis of fourpromoter region SNPs. Significant associations with acute GVHD and TRM were found for SNPs À592 and À1082 in the patient in the discovery cohort of 570 MRD cases, and this was confirmed in a second independent cohort of 423 MRD cases. An analysis of the combined cohorts (n ¼ 993) showed that the patients' IL-10/À592ÃA/A genotype was associated with a decreased risk of grades III-IV GVHD and TRM compared with the IL-10/À592ÃC/ C genotype [33] . Mullighan et al. [35] and Kim et al. [41] found no association of IL-10 genotypes with chronic, but not acute GVHD. In a study of 182 URD HCT, Keen et al. [36] reported an association of IL-10 promoter variation in the donor with TRM but not with GVHD. Bettens et al. [42] analyzed the IL10G microsatellite in 131 URD HCT and found an association of the low repeat variants (<12 alleles) in the patient with better survival. In a study of 682 URD HCT cases at our center, however, we have found no association of four IL-10 promoter-region SNPs in either patient or donor with acute GVHD or TRM (unpublished data).
Lin et al. [43] extended the analysis of the IL10 pathway by examining a coding SNP in the IL-10RB gene at cDNA position 238 (A/G). The c238ÃG allele of the donor was significantly associated with a lower risk of acute GVHD and provided protection among recipients with the high-risk IL-10/À592ÃA/C or AA genotypes but not among those with the IL-10/À592ÃC/C genotype, suggesting an interaction between the donor IL-10RB/ c238 and recipient IL-10/À592 genotypes.
Summary of immune response gene association studies with
The data reviewed above, although representing only two of the prominent candidate IRGs, TNF and IL-10, illustrates the overall problem. Similar data suggesting associations of several other IRGs with GVHD and survival including CTLA4, IFNG, IL-1, IL-1RA, IL-2, IL-6, IL-7R, NOD2 and TNFRII have been reported; however, these results like those for TNF and IL-10 are often inconsistent or lack rigorously designed validation studies [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Three recent review articles have also addressed the integration and interpretation of these several different studies [54 ,55 ] . Unfortunately, it is not possible with the cumulative data currently available to clearly distinguish true positive associations from false-positive or false-negative findings. There may be several factors contributing to this confusing situation. The most likely explanations include heterogeneity between patient populations (and differences due to unknown patient and disease risk factors such as diagnosis, prior therapy and disease stage, transplant protocols and possibly population differences or population admixture); the markers selected may be in weak linkage disequilibrium with the relevant functional variant; and small sample size and lack of sufficient statistical power. The latter is likely to be the primary reason for lack of sensitivity and the occurrence of falsepositive associations. Results from most studies are based on sample sizes of only a few hundred patients. By contrast, genetic risk studies of common immunemediated diseases such as type 1 diabetes have required samples of several thousand patients.
Future studies of genetic factors affecting graft-versushost disease
Future studies of IRG associations with GVHD and related complications and mortality will need to carefully address basic study design questions such the optimal study population, power considerations and the scope of the genetic analysis. Mullally and Ritz [54 ] , and Mullighan and Bardy [55 ] , have recently outlined the emerging technologies available for performing whole genome scans and the impact that these new approaches can have on the discovery of genes and pathways, many of which may be unknown, that critically control the strength of GVHD, HCT-related toxicity and survival. This knowledge could have great utility for predicting risk, counseling patients, guiding donor selection and the choice of alternative transplant procedure [56] . The potential for bringing personal medicine to the HCT clinic requires a comprehensive description of all the functional genetic determinants associated with GVHD and mortality, and an understanding of how these genetic factors interact with the other clinical covariables that affect HCT outcome.
Conclusion
Genetic diversity of HLA and IRGs has functional implications in URD HCT. Sequence disparity between the transplant recipient and donor for the classical class I and II genes is associated with risks of graft rejection, GVHD, and mortality. Polymorphism of IRGs modulates the strength of the inflammatory response after HCT. Optimizing URD transplantation includes consideration of the HLA match status of the recipient and donor, and avoidance of high-risk HLA mismatches. Future advances in HCT may include the incorporation of information on recipient and donor IRG variation in risk assessment and planning of the transplant procedure.
